Neuropathix
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Neuropathix generated cash of -$889,637, which is more than the previous year. Cash used in financing activities reached the amount of $889,962 last year. Net change in cash is therefore -$6,197.
Cash Flow
| 2015 | 34.71K | 0 | 12.85K |
|---|---|---|---|
| 2016 | -50.17K | 0 | 2.37K |
| 2017 | -23.27K | 0 | 25.00K |
| 2018 | -1.21M | 824.54K | 689.16K |
| 2019 | -1.89M | 1.56M | 141.19K |
| 2020 | -944.19K | 0 | 844.61K |
| 2021 | -889.63K | -6.52K | 889.96K |
NPTX Cash Flow Statement (2015 – 2021)
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 21.87K | 121.45K | 307.13K | 4.32K | 28 | 47.82K | 257 |
Operating activities | |||||||
Net income | -3.55M | -4.53M | -3.45M | 931.05K | -22.44K | -32.02K | 4.74K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 21.06K | 16.13K | 5.50K | 0 | 0 | 0 | 0 |
Stock-based compensation expense | 1.35M | 1.72M | 275.87K | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 1.35M | 1.72M | 275.87K | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 9.87K | -10K | 0 |
Inventories | 0 | 0 | 0 | 0 | 53.81K | 0 | 0 |
Accounts payable | 253.41K | 338.14K | 131.57K | -29.34K | -15.70K | 16.81K | 0 |
Cash generated by operating activities | -889.63K | -944.19K | -1.89M | -1.21M | -23.27K | -50.17K | 34.71K |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | -27.49K | -286.58B | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -6.52K | 0 | -41.95K | -3.07K | 0 | 0 | 0 |
Acquisitions Net | 0 | 0 | 41.95B | 289.65K | 0 | 0 | 0 |
Cash generated by investing activities | -6.52K | 0 | 1.56M | 824.54K | 0 | 0 | 0 |
Financing activities | |||||||
Common Stock Issued | 833.72K | 594.70B | 150B | 203K | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -68.76K | -7.53K | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 889.96K | 844.61K | 141.19K | 689.16K | 25.00K | 2.37K | 12.85K |
Net Change In Cash | -6.19K | -99.58K | -185.67K | 302.80K | 1.72K | -47.79K | 47.56K |
Cash at end of period | 15.67K | 21.87K | 121.45K | 307.13K | 1.75K | 28 | 47.82K |
| Data source | Data source | Data source | Data source | Data source | Data source |